Catch up on today's top five analyst upgrade with this list compiled by The Fly: 1. Qorvo (QRVO) and Skyworks (SWKS) upgraded to Buy from Neutral at Mizuho. 2. McKesson (MCK) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Ricky Goldwasser saying shares have underperformed the S&P in the last five years because of "a myriad of headwinds, with the most recent being concerns about opioids liability and its 2020/21 earnings power. 3. Edwards Lifesciences (EW) upgraded to Outperform from Perform at Oppenheimer. 4. Square (SQ) upgraded to Overweight from Equal Weight at Stephens with analyst Brett Huff saying he expects the company to beat revenue expectations and meet EBITDA expectations when it reports Q4 results. 5. L Brands (LB) upgraded to Buy from Hold at Deutsche Bank with analyst Tiffany Kanaga saying yesterday's holiday report, with Victoria's Secret reporting sales well below expectations, likely tips the scale "more toward a split, likely triggering strategic action in the near-term." This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

As bitcoin, ethereum and other cryptocurrencies get increasing attention from investors, Wall Street and its traditional banks continue to adjust to the shift. Catch up on... To see the rest of the story go to thefly.com. See Story Here

Sees Q2 revenue $1.62B-$1.7B, consensus $1.64B.

Reports Q1 revenue $1.6B, consensus $1.57B. "Edwards is positioned to extend our leadership and deliver sustainable growth as a result of the strategic investments we have made across our transcatheter platforms to address the large and growing needs of patients impacted by aortic, mitral and tricuspid disease. We are pleased with our total company performance with first quarter sales growth of 10% as more patients were treated with our innovative therapies," said Bernard Zovighian, CEO. "This encouraging start to the year supports our increased 2024 sales guidance. Looking beyond 2024, we remain confident in Edwards' innovation-driven strategy, led by new indications, differentiated technologies and strategic adjacencies for addressing the significant unmet needs of structural heart disease patients."

Pre-earnings options volume in Edwards Lifesciences is 5.5x normal with puts leading calls 10:7. Implied volatility suggests the market is anticipating a move near 4.8%, or $4.27, after results are released. Median move over the past eight quarters is 6.3%.